echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > AstraZeneta entered Phase I clinically in the study of COVID-19 antibody cocktail therapy.

    AstraZeneta entered Phase I clinically in the study of COVID-19 antibody cocktail therapy.

    • Last Update: 2020-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    AZD7442 is an antibody cocktail therapy for the prevention and treatment of COVID-19, consisting of 2 monoclonal antibodies from patients in the recovery phase of SARS-CoV-2 infection.
    two types of monoantigens were discovered by Vanderbilt University Medical Center and licensed to AstraZeneta in June 2020.
    AstraZeneca optimized these two monoantibodies, extending their half-life and reducing Fc-subject binding.
    with extended half-life should provide protection against COVID-19 for at least 6 months.
    In a recent study published in the journal Nature, the two monoants were clinically shown to block the binding of SARS-CoV-2 viruses to host cells and protect against infection in cell and animal disease models.
    AZD7442 has the potential to provide a preventive therapy for people exposed to SARS-CoV-2 virus, as well as a treatment for patients infected with SARS-CoV-2 virus and to prevent the progression of the disease.
    If AZD7742 is shown to be toned and safe in trials, AstraZeneta will enter larger Phase II and III clinical trials to assess the effectiveness of AZD7742 as a potential therapy for the prevention and treatment of COVID-19.
    "This trial is an important milestone in our development of a monoclonal antibody combination for the prevention or treatment of COVID-19," said Mene Pangalos, Executive Vice President, Biopharmaceutical Research and Development, AstraZenecon.
    addition to reducing the likelihood of viral resistance, this combination of antibodies, coupled with our proprietary half-life extension technology, has the potential to improve the effectiveness and durability of use.
    " In addition to AstraZeneone, Regeneratives is also developing a COVID-19 antibody cocktail therapy REGN-COV2, which consists of two monoantigens, targeting two separate, non-overlapping bits in the SARS-CoV-2 ratchet protein binding region, which has synergies and reduces the risk of virus mutation escape.
    non-human primate data show that REGN-COV2 can prevent SARS-CoV-2 infection and treat infected animals by accelerating virus removal.
    REGN-COV2 has been developed to treat and prevent COVID-19 infections.
    currently, two Phase II/III clinical trials are being evaluated for the treatment of COVID-19 and one Phase III clinical trial is being evaluated for the prevention of COVID-19 in family contacts of infected persons.
    the middle of this month, Roche and Regeneration reached a partnership to develop, manufacture and distribute REGEN-COV2 around the world.
    the therapy promises to provide an urgently needed treatment option for people who already have symptoms of COVID-19 and has the potential to slow the spread of the global pandemic by preventing infection among people at high risk of exposure to the virus.
    , the two sides will increase the supply of REN-COV2 by at least 3.5 times from its current capacity and have the potential to further expand capacity, according to a joint statement.
    will greatly increase the available doses for people in the United States and around the world.
    original origin: Phase I clinical trial launched for monoclonal antibody combination for the prevention and treatment of COVID-19 Original title: AstraZeneven antibody cocktail therapy AZD7442 enters Phase I clinical: treatment and prevention COVID-19!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.